At Visiogene, we are dedicated to pioneering biotechnological advancements for a healthier future.

Visiogene is a vertically integrated biotechnology company developing gene and protein delivery technologies as well as therapies for blindness.  We are leveraging our patented technologies of retinal penetrating Adeno-Associated Viruses (AAV-IKV)  that can deliver genes to the outer retina including photoreceptors via an intravitreal injection and a novel chaperone known as Nuc1 that can facilitate the delivery of small molecules and large proteins into retinal cells in vivo